Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

British Journal of Cancer

Volumn 67, Issue 3, 1993, Pages 560-563

  O'Rourke N P ^a   McCloskey, E V ^a   Vasikaran, S ^a   Eyres, K ^a   Fern, D ^a   Kanis, J A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CLODRONIC ACID; CREATININE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SERUM; URINE;

ADULT; AGED; CALCIUM; CLODRONIC ACID; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; HYPERCALCEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0027534523     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.102     Document Type: Article

References (25)

1. BONJOUR, J.P., RIZZOLI, R. & JUNG, A. (1984). Diphosphonate therapy in hypercalcaemia of malignancy and tumour osteolysis. Trends Pharmacol. Sci., 5, 509-511.
2. BONJOUR, J.P., PHILLIPPE, J., GUELPA, G., BISETTI, A., RIZZOLI, R., JUNG, A., ROSINI, S. & KANIS, J.A. (1988). Bone and renal components in hypercalcaemia of malignancy and responses to a single infusion of clodronate. Bone, 9, 123-130.
3. BONJOUR, J.P. & RIZZOLI, R. (1989). Pathophysiological aspects and therapeutic approaches of tumoral osteolysis and hypercalcemia. Recent Results in Cancer Res., 116, 29-39.
4. BONJOUR, J.P. & RIZZOLI, R. (1991). Treatment of hypercalcaemia of malignancy with clodronate. Bone, 12 (suppl 1), S19-23.
5. COLEMAN, R E. & RUBENS, P.D. (1987). APD for hypercalcaemia of breast cancer. Br. J. Cancer, 56, 465-469.
6. ELOMAA, I., BLOMQVIST, C., PORKKA, L., LAMBERG-ALLARDT, C. & BORGSTROM, G.H. (1987). Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone, 8 (suppl), 53-56.
7. GALLACHER, S.J., RALSTON, S.H., PATEL, U. & BOYLE, I T. (1989). Side effects of pamidronate. Lancet, ii, 42.
8. KANIS, J.A. & YATES, A.J.P. (1985). Measuring serum calcium. Br. Med. J., 290, 728-729.
9. KANIS, J.A., URWIN, G.H., GRAY, R.E.S., BENETON, M.N.C., MCCLOSKEY, E.V., HAMDY, N.A.T. & MURRAY, S.A. (1987). Effects of intravenous etidronate on skeletal and calcium metabolism. Amer. J. Med., 82, 55-70.
10. KANIS, J.A., MCCLOSKEY, E.V. & PATERSON, A.H.G. (1990). Use of diphosphonates in hypercalcaemia due to malignancy. Lancet, i, 170-171.
11. KANIS, J.A., MCCLOSKEY, E.V., O’ROURKE, N., PRESTON, E., GREAVES, M., EYRES, K. & VASIKARAN, S. (1991). Bisphosphonates in the management of hypercalcaemia of malignancy. In Tumour Induced Hypercalcaemia and its Management, (eds). Russell, R.G.G. & Kanis, J.A. Royal Society of Medicine: London, pp.59-70.
12. MARTIN, T.J., EBELING, P R., RODDA, C.P. & KEMP, B.E. (1988). Humoral hypercalcaemia of malignancy: involvement of a novel hormone. Austr. N. Z. J. Med., 3, 287.
13. MORTON, A., DODWELL, D.J. & HOWELL, A. (1989). Disodium pamidronate for the management of hypercalcaemia of malignancy: comparative studies of single dose versus daily infusions and of infusion duration. In Disodium Pamidronate in the Treatment of Malignancy-Related Disorders. Burckhardt (ed). pp. 85-100. Hans Huber: Berne.
14. MUNDY, G.R., IBBOTSON, K.J., D’SOUZA, S.M., SIMPSON, E.L., JACOBS, J.W. & MARTIN, T.J. (1984). The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N. Engl. J. Med., 310, 1718-1727.
15. PERCIVAL, R.C., YATES, A.J.P., GRAY, R.E.S., GALLOWAY, J., ROGERS, K., NEAL, F.E. & KANIS, J.A. (1985). Mechanisms of malignant hypercalcaemia in carcinoma of the breast. Br. Med. J., 291, 776-779.
16. PRESTON, C.J., YATES, A.J.P., BENETON, M.N.C., RUSSELL, R.G.G., GRAY, R.E.S., SMITH, J. & KANIS, J.A. (1986). Effective shortterm treatment of Paget’s disease with oral etidronate. Br. Med. J., 292, 79-80.
17. RALSTON, S.H., GALLACHER, S.J., PATEL, U., DRYBURGH, F.J., FRASER, W.D., CAVAN, R.A. & BOYLE, I T. (1989). Comparison of three intravenous bisphosphonates in cancer associated hypercalcaemia. Lancet, ii, 1180-1182.
18. RUSSEL, R.G.G., SMITH, R., PRESTON, C., WALTON, R.J. & WOODS, C.G. (1974). Diphosphonates in Paget’s disease. Lancet, i, 894-898.
19. SINGER, F.R., RITCH, P.S., LAD, T.E., RINGENBERG, Q.S., SCHILLER, J.H., RECKER, R.R. & RYZEN, E. (1991). Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled multicenter study. The hypercalcaemia study group. Arch. Intern. Med., 151, 471-476.
20. STEWART, A.F., HORST, R., DEFTOS, L.J., LANG, R. & BROADUS, A.E. (1980). Biochemical evaluation of patients with cancer associated hypercalcemia: evidence for humoral and non-humoral sub-groups. N. Engl. J. Med., 303, 1377-1383.
21. THIEBAUD, D., LEYVRAZ, S., VAN FLIEDNER, V., PERCY, L., CORNU, P., THIEBAUD, S. & BURCKHARDT, P. (1991). Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur. J. Cancer, 27, 37-41.
22. URWIN, G.H., YATES, A.J.P., GRAY, R.E.S., HAMDY, N.A.T., MCCLOSKEY, E.V., PRESTON, F.E., GREAVES, M., NEAL, F.E. & KANIS, J.A. (1987). Treatment of hypercalcaemia of malignancy with intravenous clodronate. Bone, 8 (suppl 1), S43-53.
23. VAN HOLTEN-VERZANTVOORT, A T., BIJVOET, O.L., CLETON, F.J., HERMANS, J., KROON, H.M., HARINCK, H I., VERMEY, P., ELTE, J.W., NEIJT, J.P., BEEX, L.V. & BLIJHAM, G. (1987). Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate treatment. Lancet, ii, 983-985.
24. YATES, A.J.P., GUTIERREZ, G.E., SMOLENS, P., TRAVIS, P.S., KATZ, M.S., AUFDEMORTE, T.B., BOYCE, B.F., HYMER, T.K., POSER, J.W. & MUNDY, G.R. (1988). Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism in vivo and in vitro. J. Clin. Invest., 81, 932-938.
25. ZEIGLER, R. & SCHARLA, S.H. (1989). Treatment of tumor hypercalcaemia with clodronate. Recent Results Cancer Res., 116, 46-54.